OncoMatch/Clinical Trials/NCT07747740
Sequential Gemcitabine Plus Docetaxel Versus Gemcitabine Plus Mitomycin C for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer
Is NCT07747740 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies multiple treatments including Gemcitabin and Docetaxel for non-muscle-invasive bladder cancer.
Treatment: Gemcitabin · Docetaxel · Mitomicin C — This prospective, randomized, open-label, phase II clinical trial compares two sequential intravesical chemotherapy regimens in patients with bacillus Calmette-Guérin (BCG)-unresponsive high-grade non-muscle-invasive bladder cancer (NMIBC) following complete transurethral resection of bladder tumor (TURBT). Participants are randomized in a 1:1 ratio to receive sequential intravesical gemcitabine plus docetaxel or sequential intravesical gemcitabine plus mitomycin C. The primary objective is to compare 12-month event-free survival between treatment groups. Secondary objectives include evaluation of cystectomy-free survival, progression-free survival, treatment safety, tolerability, and patient-reported quality of life.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Urothelial Carcinoma
Disease stage
Required: Stage NON-MUSCLE-INVASIVE
Excluded: Stage MUSCLE-INVASIVE (≥T2), III, IV
Histologically confirmed BCG-unresponsive non-muscle-invasive urothelial bladder cancer (NMIBC)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07747740 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage NON-MUSCLE-INVASIVE is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages